Besides tumor cell MHC expression, we also investigated the predictive potential of a panel of immune cell markers and found a significant association with response to anti-PD-1 therapy in the case of eight of the ten immune cell types studied: CD8+ and CD45RO+ T lymphocytes, regulatory T cells (FOXP3+), CD20+ B lymphocytes, and cells expressing activation markers/immune checkpoints CD134, PD-1, PD-L1, and CD103, a marker of tissue-resident T cells. This evidence concerns the gene CD8A and neoplasm.